GLUE — Monte Rosa Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1826457 ·
Last close
$16.52
Market Cap
$1.40B
52W High
$25.22
52W Low
$14.87
ADV30
1,755,936
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,210,000 | — | -50,034,000 | -44,503,000 | 736,428,000 | 159,859,000 | 214,512,000 |
| Dec 2025 | 2,781,000 | — | -49,715,000 | -46,135,000 | 448,659,000 | 129,883,000 | 215,603,000 |
| Sep 2025 | 12,768,000 | — | -32,975,000 | -27,081,000 | 459,841,000 | 208,343,000 | 214,004,000 |
| Jun 2025 | 23,194,000 | — | -15,554,000 | -12,295,000 | 359,586,000 | 69,429,000 | 91,506,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,798,000
Investing CF
$-101,833,000
Financing CF
$30,351,000
CapEx
$-4,700,000
Dividends Paid
—
Buybacks
$-357,000
EPS Diluted TTM
$-0.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-477,214,000
Inventory
—
Receivables
$11,600,000
ST Investments
$247,221,000
EBIT TTM
$-54,208,000
Pretax Income TTM
$-39,723,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$42,953,000
EBITDA
$-139,940,992
Free Cash Flow
$-61,151,752
Enterprise Value
$1,288,837,248
Total Cash
$666,220,032
Total Debt
$39,064,000
Shares Out
84,479,418
Trailing EPS
$-1.48
Book Value
$6.19
ROE
-32.6%
ROA
-16.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 123,672,000 | -54,208,000 | -38,626,000 | 448,659,000 | 215,603,000 | — | -22,798,000 |
| Dec 2024 | 75,622,000 | -81,112,000 | -72,700,000 | 438,732,000 | 215,796,000 | — | 41,996,000 |
| Dec 2023 | 0 | -143,311,000 | -135,352,000 | 303,755,000 | 124,505,000 | — | -43,802,000 |
| Dec 2022 | 0 | -112,384,000 | -108,501,000 | 342,389,000 | 70,976,000 | — | -92,466,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALVO | Alvotech | $1.39B | $4.12 | — |
| VIR | Vir Biotechnology, Inc. | $1.46B | $8.66 | — |
| SLBT | SL Science Holding Ltd | $1.48B | $2.64 | — |
| MAZE | Maze Therapeutics, Inc. | $1.49B | $26.92 | — |
| DBVTF | DBV Technologies S.A. | $1.26B | $4.26 | — |
News headlines (Yahoo Finance, 1h cache)
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
2026-07-31 21:56 · Yahoo
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
2026-07-31 18:24 · Yahoo
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:01 · Yahoo
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
2026-06-29 22:50 · Yahoo
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
2026-06-03 18:00 · Yahoo
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
2026-05-20 11:00 · Yahoo
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
2026-05-10 00:24 · Yahoo
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 15:15 · Yahoo
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
2026-05-07 11:00 · Yahoo
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
2026-05-06 00:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.